AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Non-small cell lung cancer (NSCLC) tumors harboring mutations in EGFR ultimately relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs). Here, we show that resistant cells without the p.T790M or other acquired mutations are sensitive to the Aurora B (AURKB) inhibitors barasertib and S49...

全面介紹

Na minha lista:
書目詳細資料
發表在:Nat Commun
Main Authors: Bertran-Alamillo, Jordi, Cattan, Valérie, Schoumacher, Marie, Codony-Servat, Jordi, Giménez-Capitán, Ana, Cantero, Frédérique, Burbridge, Mike, Rodríguez, Sonia, Teixidó, Cristina, Roman, Ruth, Castellví, Josep, García-Román, Silvia, Codony-Servat, Carles, Viteri, Santiago, Cardona, Andrés-Felipe, Karachaliou, Niki, Rosell, Rafael, Molina-Vila, Miguel-Angel
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2019
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6472415/
https://ncbi.nlm.nih.gov/pubmed/31000705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-019-09734-5
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍